iVEAcare

Executive Summary

iVEAcare is a private, clinical-stage medical device company developing next-generation neuromodulation platforms to address chronic diseases. Founded in 2018 and headquartered in San Francisco, the company targets large, underserved patient populations with unmet clinical needs. Its leadership team brings deep experience from the implantable medical device industry, with a strong track record in product development and commercialization. iVEAcare's bioelectronic therapies aim to provide minimally invasive, durable treatment options for conditions such as chronic pain, neurological disorders, and metabolic diseases. While the company remains in early clinical stages, its proprietary technology and experienced team position it to potentially disrupt the neuromodulation market, which is projected to grow significantly over the next decade. The lack of disclosed funding rounds or valuation suggests a lean operation, but the company's focus on validated mechanisms and clinical evidence generation may attract strategic partnerships or later-stage investment as data matures.

Upcoming Catalysts (preview)

• Q3 2026Initial clinical trial results for lead neuromodulation platform70% success
• Q3 2026FDA breakthrough device designation or IDE approval60% success
• Q4 2026Key opinion leader publication or symposium presentation80% success